Financial Results Briefing for FY2025 (March 2026)

FY2025 Financial Results Overview

Sales revenue for FY2025 was ¥453.3 billion (up 13.7% YoY), operating income was ¥107.3 billion (up 272.6% YoY), and net income attributable to owners of the parent was ¥106.9 billion (up 352.2% YoY). The increase in sales revenue was driven by the growth of Orgovirx, GemTesa, and the increase in milestone revenue. Selling, general, and administrative expenses decreased due to structural improvements and partial business transfers. Regionally, North America saw significant growth, while Japan declined; overall, both revenue and profit increased.

FY2026 Performance Forecast and Growth Strategy

For FY2026, sales revenue is projected to reach ¥540.0 billion (up 19.1% YoY), operating income to ¥90.0 billion (down 16.2% YoY), and net income attributable to owners of the parent to ¥77.0 billion (down 27.9% YoY). The revenue growth predominantly stems from the expansion of Orgovirx and GemTesa in North America. Conversely, profit margins are affected by increased R&D expenses, currency exchange impacts, and higher selling expenses. The company emphasizes mid- to long-term growth investments, including fundamental structural reforms, nurturing next-generation growth engines, and strengthening its financial base.